MediWound Secures $3.3M U.S. Funding for Room-Temp NexoBrid
MDWD is trading near its 52-week low of $12.52 (6.3% above the low).
Summary
MediWound received an additional $3.3M from a U.S. Department to develop a room-temperature-stable NexoBrid formulation, bringing the program total to $21.8M. The non-dilutive funding targets IND-enabling work for field use, removing cold-chain limitations and expanding potential deployment settings. This follows Q2 revenue decline and reaffirmed guidance, but the new capital de-risks development without shareholder dilution. The room-temp formulation could unlock broader military and emergency use, complementing the existing BARDA/Vericel contract. Watch for IND submission and clinical progress on the room-temp version.
At the time of this announcement, MDWD was trading at $13.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.8M. The 52-week trading range was $12.52 to $20.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.